Clinical trials: Opioid Use Disorder (OUD)
Substance Use, Substance Use Disorders
Peer-Delivered Behavioral Activation for Methadone Adherence - Pilot Phase
The purpose of this study is to evaluate the feasibility and effectiveness of a peer-led, brief, behavioral intervention to improve adherence to medication for opioid use disorder (MOUD) among low-income, minoritized individuals…
- Conditions
- Substance Use, Substance Use Disorders, Opioid-use Disorder, Peer Delivered
- Trial name
- HEAL Together (NCT04248933)
- Testing
- Peer-Delivered Behavioral Activation (Peer Activate)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Maryland, College Park
Community Reinforcement And Family Training, Family Health
Scalable Digital Delivery of Evidence-based Training for Professionals to Maximize Treatment Rates of OUD in Families
The goal of this project is to develop and evaluate the technical feasibility and commercial viability of a scalable digital counselor training program for CRAFT.
- Conditions
- Community Reinforcement And Family Training, Family Health, Substance-Related Disorders
- Trial name
- NCT05875142
- Testing
- Behavioral: Digital Tutorial Overview, Behavioral: Training Materials, Behavioral: Feedback and Coaching
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- We The Village, Inc.
Opioid Use Disorder, Stimulant Use Disorder
Suvorexant for Opioid/Stimulant Co-use
This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.
- Trial name
- NCT05546515
- Testing
- Suvorexant (dual orexin receptor antagonist)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Opioid Use Disorder
Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants
The purpose of this open label study is to characterise the absorption, metabolism, excretion, and mass balance of [14C]-IDV184001AN ([14C]-IDV184001) in healthy adult male participants.
- Trial name
- NCT05974046
- Testing
- [14C]IDV184001AN
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Opioid-Use Disorder
Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD
Background: People with opioid-use disorder (OUD) might benefit from having more treatment drugs to choose from. A new drug, TRV734, could be used like methadone to treat OUD. It might not have as many side effects.
- Trial name
- NCT04316559
- Testing
- TRV734, Oxycodone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Substance-Related Disorders, Substance Use Disorders
Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders
Subjects in this study will be patients with opioid use disorders (OUDs) based on DSM-5 criteria recruited from the greater Atlanta metropolitan region.
- Conditions
- Substance-Related Disorders, Substance Use Disorders, Substance Abuse, Intravenous, Substance Withdrawal
- Trial name
- nVNS in OUDs (NCT04556552)
- Testing
- Non invasive VN stimulation (nVNS), Oxygen (15-O) Water
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Opioid-use Disorder
Treatment of Pregnant Women With OUD
The investigators are testing two models of support for pregnant women with an opioid use disorder (OUD)
- Trial name
- SMART (NCT04240392)
- Testing
- Collaborative Care (CC), Extension for Community Healthcare Outcomes (ECHO)
- Where
- 11 sites in United States
- Volunteers
- 230 people
- Sponsor
- Yale University
Opioid-Use Disorder (OUD)
SafetyNet Program for Opioid Use Disorder (OUD)
The principal aim of this study is to determine whether a novel biopsychosocial intervention following opioid overdose (OD) affects 1) the frequency of secondary opioid OD events and 2) the proportion of individuals who remain…
- Trial name
- NCT04253782
- Testing
- Team Intervention
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Yale University
Opioid-use Disorder, Contingency Management
Usability Testing for the Reward-based Technology to Improve OUD Treatment
Millions of people in the US misuse opioids each year, leading to thousands of deaths and costing billions of dollars in total economic burden.
- Conditions
- Opioid-use Disorder, Contingency Management, Medication for Opioid-use Disorder
- Trial name
- OARSCM (NCT05159362)
- Testing
- Software Application
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Q2i, LLC
Opioid Use Disorder
Reward-based Technology to Improve OUD Treatment
Millions of people in the US misuse opioids each year. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common…
- Trial name
- OARSCM (NCT05180669)
- Testing
- OARSCM Software Application, MyMAT Software Application
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Q2i, LLC
Opioid-use Disorder
Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder
This proposal aims to determine whether an adjunctive Mindfulness-Based Relapse Prevention (MBRP) treatment program improves Medication Assisted Treatment (MAT) adherence and reduces drug-use among opioid use disorder (OUD)…
- Trial name
- NCT05042388
- Testing
- Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA), Treatment-As-Usual
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- West Chester University of Pennsylvania
Sleep Disorder, Restless Legs Syndrome
Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD
The investigators propose to test the use of pramipexole in patients being treated for Opioid Use Disorder to test its ability to reduce symptoms of both Restless Legs Syndrome and protracted opioid withdrawal and thereby promote…
- Conditions
- Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
- Trial name
- NCT04759703
- Testing
- Pramipexole
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts General Hospital
Hepatitis C, Chronic, Opioid-use Disorder
Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection
Incorporating Hepatitis C Virus (HCV) treatment into opioid maintenance treatment program clinical protocols is an innovative health care delivery model that has been associated with improved HCV treatment uptake in non-pregnant…
- Trial name
- NCT03057847
- Testing
- Sofosbuvir/Velpatasvir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Elizabeth Krans, MD
Opioid-Related Disorders, Opioid Dependence
An Innovative Intervention for OUD Treatment
The Bridge Device (BD) is a neuromodulator medical device that has been cleared by the FDA for Opioid Use Disorder (OUD) treatment.
- Conditions
- Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
- Trial name
- Bridge (NCT04325659)
- Testing
- Bridge Device, Lofexidine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Opioid Use, Opioid-use Disorder
Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0
This study integrates the Mental Health Research Network (MHRN) suicide risk models into Opioid Wizard, an electronic health record (EHR) clinical decision support (CDS) to identify and treat patients at high risk of opioid use…
- Conditions
- Opioid Use, Opioid-use Disorder, Suicide
- Trial name
- NCT04939727
- Testing
- OUD-CDS + Suicide Risk Model associated CDS
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- HealthPartners Institute
Opioid Use Disorder
STAMPS: South Carolina Buprenorphine Treatment Initiation, Adherence, and Retention Utilizing Mobile Health Units and Peer Support Specialists
The study is a 1-arm prospective interventional cohort quasi-experimental with retrospective control group. Enrolled participants will be compared to previously established mobile health patients, who did not work with a peer…
- Trial name
- NCT06384781
- Testing
- Peer Support Checklist
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Prisma Health-Upstate
Clinical Decision Support, Buprenorphine
Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD
Emergency Departments (EDs) frequently care for individuals with Opioid Use Disorder (OUD). Buprenorphine (BUP) is an effective treatment option for patients with OUD that can safely be initiated in the ED.
- Conditions
- Clinical Decision Support, Buprenorphine, Opioid-use Disorder
- Trial name
- EMBED (NCT03658642)
- Testing
- Clinical Decision Support (CDS)
- Where
- 22 sites in United States
- Volunteers
- 5,047 people
- Sponsor
- Yale University
Opioid Use Disorder
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
- Trial name
- NCT05924945
- Testing
- Bridge™ active device
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masimo Corporation
Opioid Use Disorder (OUD)
HEALing Communities Study
This study will test the impact of implementing the Communities That Helping to End Addiction Long-term (HEAL) intervention on opioid overdose deaths within 67 highly affected communities with the goal of reducing opioid overdose…
- Trial name
- NCT04111939
- Testing
- Communities That HEAL, Wait-list control
- Where
- 4 sites in United States
- Volunteers
- 67 people
- Sponsor
- RTI International
Opioid Use Disorder (OUD)
A Safety Study of AZD4041 in Healthy Participants
This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study in healthy male and female adult participants.
- Trial name
- NCT05233085
- Testing
- AZD4041
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca